Cargando…

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview

The availability of long-acting injectable (LAI) antipsychotics for the treatment of schizophrenia provides clinicians with options that deliver continuous drug exposure and may improve adherence compared with daily oral antipsychotics. However, all LAI antipsychotics have unique formulations and ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Correll, Christoph U., Kim, Edward, Sliwa, Jennifer Kern, Hamm, Wayne, Gopal, Srihari, Mathews, Maju, Venkatasubramanian, Raja, Saklad, Stephen R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873121/
https://www.ncbi.nlm.nih.gov/pubmed/33507525
http://dx.doi.org/10.1007/s40263-020-00779-5
_version_ 1783649328598876160
author Correll, Christoph U.
Kim, Edward
Sliwa, Jennifer Kern
Hamm, Wayne
Gopal, Srihari
Mathews, Maju
Venkatasubramanian, Raja
Saklad, Stephen R.
author_facet Correll, Christoph U.
Kim, Edward
Sliwa, Jennifer Kern
Hamm, Wayne
Gopal, Srihari
Mathews, Maju
Venkatasubramanian, Raja
Saklad, Stephen R.
author_sort Correll, Christoph U.
collection PubMed
description The availability of long-acting injectable (LAI) antipsychotics for the treatment of schizophrenia provides clinicians with options that deliver continuous drug exposure and may improve adherence compared with daily oral antipsychotics. However, all LAI antipsychotics have unique formulations and pharmacokinetic characteristics that have implications for medication selection, administration interval, and injection site. This review outlines key differences in drug formulations and pharmacokinetics among LAI antipsychotics. A systematic search of the PubMed database was conducted to identify physical and formulation properties and pharmacokinetic data of commercially available LAI antipsychotics, including flupentixol decanoate, fluphenazine decanoate, haloperidol decanoate, zuclopenthixol decanoate, aripiprazole monohydrate, aripiprazole lauroxil, olanzapine pamoate, paliperidone palmitate, risperidone microspheres, and risperidone polymeric microspheres. Additional information was obtained from package inserts and product monographs. Relevant data on drug properties, administration details, pharmacokinetic parameters, and oral dose equivalencies of LAI antipsychotics are summarized. Based on our analysis, formulation characteristics (e.g., vehicle medium) and administration characteristics (e.g., injection site) can affect rate of absorption and adverse effects and may factor into whether oral supplementation or an additional injection is needed. Dose adjustments may be necessary based on potential drug–drug interactions, and approximate dose equivalence with oral formulations can help inform titration when switching from oral to LAI formulations. Clinicians administering LAI antipsychotics should consider these formulation and pharmacokinetic factors to maximize clinical impact and to adjust to an individual patient’s needs and treatment goals. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40263-020-00779-5.
format Online
Article
Text
id pubmed-7873121
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-78731212021-02-22 Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview Correll, Christoph U. Kim, Edward Sliwa, Jennifer Kern Hamm, Wayne Gopal, Srihari Mathews, Maju Venkatasubramanian, Raja Saklad, Stephen R. CNS Drugs Review Article The availability of long-acting injectable (LAI) antipsychotics for the treatment of schizophrenia provides clinicians with options that deliver continuous drug exposure and may improve adherence compared with daily oral antipsychotics. However, all LAI antipsychotics have unique formulations and pharmacokinetic characteristics that have implications for medication selection, administration interval, and injection site. This review outlines key differences in drug formulations and pharmacokinetics among LAI antipsychotics. A systematic search of the PubMed database was conducted to identify physical and formulation properties and pharmacokinetic data of commercially available LAI antipsychotics, including flupentixol decanoate, fluphenazine decanoate, haloperidol decanoate, zuclopenthixol decanoate, aripiprazole monohydrate, aripiprazole lauroxil, olanzapine pamoate, paliperidone palmitate, risperidone microspheres, and risperidone polymeric microspheres. Additional information was obtained from package inserts and product monographs. Relevant data on drug properties, administration details, pharmacokinetic parameters, and oral dose equivalencies of LAI antipsychotics are summarized. Based on our analysis, formulation characteristics (e.g., vehicle medium) and administration characteristics (e.g., injection site) can affect rate of absorption and adverse effects and may factor into whether oral supplementation or an additional injection is needed. Dose adjustments may be necessary based on potential drug–drug interactions, and approximate dose equivalence with oral formulations can help inform titration when switching from oral to LAI formulations. Clinicians administering LAI antipsychotics should consider these formulation and pharmacokinetic factors to maximize clinical impact and to adjust to an individual patient’s needs and treatment goals. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40263-020-00779-5. Springer International Publishing 2021-01-28 2021 /pmc/articles/PMC7873121/ /pubmed/33507525 http://dx.doi.org/10.1007/s40263-020-00779-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review Article
Correll, Christoph U.
Kim, Edward
Sliwa, Jennifer Kern
Hamm, Wayne
Gopal, Srihari
Mathews, Maju
Venkatasubramanian, Raja
Saklad, Stephen R.
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
title Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
title_full Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
title_fullStr Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
title_full_unstemmed Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
title_short Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
title_sort pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873121/
https://www.ncbi.nlm.nih.gov/pubmed/33507525
http://dx.doi.org/10.1007/s40263-020-00779-5
work_keys_str_mv AT correllchristophu pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview
AT kimedward pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview
AT sliwajenniferkern pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview
AT hammwayne pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview
AT gopalsrihari pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview
AT mathewsmaju pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview
AT venkatasubramanianraja pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview
AT sakladstephenr pharmacokineticcharacteristicsoflongactinginjectableantipsychoticsforschizophreniaanoverview